What is it about?
Prognosis of primary liver cancer (PLC) remains poor due to resistance to available therapeutics. Based on these limitations, emerging research is focused on cell origins, molecular classification and tumorigenesis, as well as tumor heterogeneity, metastasis and therapeutic resistance.
Featured Image
Why is it important?
The rapid progress and validity of next-generation sequencing (NGS) to identify genetic and genomic heterogeneity, as well as genome-wide mutational landscape, have contributed to our understanding of the molecular mechanisms that underline therapeutic resistance and relapse.
Perspectives
Strategic designs to discover novel oncotargets shape an early drug development concept for precision therapies by targeting an individual patient’s genomic alterations (GAs).
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Novel translational therapeutic strategy by sequencing primary liver cancer genomes, Future Oncology, May 2017, Future Medicine,
DOI: 10.2217/fon-2017-0087.
You can read the full text:
Contributors
The following have contributed to this page
